ELAC2 and prostate cancer: In humans, mutations in ELAC2 are associated with hypertrophic cardiomyopathy (Haack et al., 2013; Shinwari et al., 2017; Saoura et al., 2019) and prostate cancer (Tavtigian et al., 2001; Korver et al., 2003; Noda et al., 2006) while in C. elegans, loss of HOE-1 has been shown to compromise fertility (Smith and Levitan, 2004).